# Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

> **NCT05117242** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 125 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic

## Interventions

- **BIOLOGICAL:** Acasunlimab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05117242
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-27
- **Primary completion:** 2024-12-02
- **Final completion:** 2026-08-30
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117242, "Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05117242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*